This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Image: Bigstock
New Strong Buy Stocks for December 20th
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Stifel Financial Corp. (SF - Free Report) : This financial services and bank holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 1.8% over the last 60 days.
Stifel Financial Corporation Price and Consensus
Stifel Financial Corporation price-consensus-chart | Stifel Financial Corporation Quote
BRT Apartments Corp. (BRT - Free Report) : This real estate investment trust has seen the Zacks Consensus Estimate for its current year earnings increasing 19.7% over the last 60 days.
BRT Realty Trust Price and Consensus
BRT Realty Trust price-consensus-chart | BRT Realty Trust Quote
Columbus McKinnon Corporation (CMCO - Free Report) : This manufacturer of actuators, cranes, rigging tools, digital power control systems, and other material handling products has seen the Zacks Consensus Estimate for its current year earnings increasing 1% over the last 60 days.
Columbus McKinnon Corporation Price and Consensus
Columbus McKinnon Corporation price-consensus-chart | Columbus McKinnon Corporation Quote
CRA International, Inc. (CRAI - Free Report) : This consulting company has seen the Zacks Consensus Estimate for its current year earnings increasing 2.6% over the last 60 days.
CRA International,Inc. Price and Consensus
CRA International,Inc. price-consensus-chart | CRA International,Inc. Quote
Donaldson Company, Inc. (DCI - Free Report) : This manufacturer of filtration systems and replacement parts has seen the Zacks Consensus Estimate for its current year earnings increasing 5.9% over the last 60 days.
Donaldson Company, Inc. Price and Consensus
Donaldson Company, Inc. price-consensus-chart | Donaldson Company, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>